These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27994442)

  • 1. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013.
    Suh HY; Peck CC; Yu KS; Lee H
    Drug Des Devel Ther; 2016; 10():4005-4016. PubMed ID: 27994442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
    Tosi D; Laghzali Y; Vinches M; Alexandre M; Homicsko K; Fasolo A; Del Conte G; Durigova A; Hayaoui N; Gourgou S; Gianni L; Mollevi C
    J Clin Oncol; 2015 Jul; 33(19):2158-65. PubMed ID: 26014300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
    Schaller TH; Snyder DJ; Spasojevic I; Gedeon PC; Sanchez-Perez L; Sampson JH
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.
    Leach MW; Clarke DO; Dudal S; Han C; Li C; Yang Z; Brennan FR; Bailey WJ; Chen Y; Deslandes A; Loberg LI; Mayawala K; Rogge MC; Todd M; Chemuturi NV
    Clin Pharmacol Ther; 2021 Jun; 109(6):1395-1415. PubMed ID: 32757299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An FDA oncology analysis of immune activating products and first-in-human dose selection.
    Saber H; Gudi R; Manning M; Wearne E; Leighton JK
    Regul Toxicol Pharmacol; 2016 Nov; 81():448-456. PubMed ID: 27743776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human dose: current status review for better future perspectives.
    Mishra A; Sarangi SC; Reeta K
    Eur J Clin Pharmacol; 2020 Sep; 76(9):1237-1243. PubMed ID: 32488334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
    Saber H; Del Valle P; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
    Agoram BM
    Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.
    Brennan FR; Morton LD; Spindeldreher S; Kiessling A; Allenspach R; Hey A; Muller PY; Frings W; Sims J
    MAbs; 2010; 2(3):233-55. PubMed ID: 20421713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
    Viala M; Vinches M; Alexandre M; Mollevi C; Durigova A; Hayaoui N; Homicsko K; Cuenant A; Gongora C; Gianni L; Tosi D
    Br J Cancer; 2018 Mar; 118(5):679-697. PubMed ID: 29438365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Models for Repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs.
    Pizzo F; Benfenati E
    Methods Mol Biol; 2016; 1425():163-76. PubMed ID: 27311467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
    Wang DD; Zhang S; Zhao H; Men AY; Parivar K
    J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A brief survey of first-in-human studies.
    Wexler D; Bertelsen KM
    J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
    Hansen AR; Cook N; Ricci MS; Razak A; Le Tourneau C; McKeever K; Roskos L; Dixit R; Siu LL; Hinrichs MJ
    Oncologist; 2015 Jun; 20(6):653-9. PubMed ID: 25964306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
    Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
    J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Hypoglycemic Studies of Polyherbal Phytoceuticals, Their Pharmacokinetic Studies and Dose Extrapolation by Allometric Scaling.
    De B; Bhandari K; Katakam P; Mitra A
    Curr Drug Discov Technol; 2017; 14(4):277-292. PubMed ID: 28359233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.